Anti-COVID Nicotine?
A growing number of people are raising the prospect that nicotine might be useful in combatting the symptoms of COVID-19, research is planned to see if it’s true
-
by Dave Cross
Share on:
Recently, POTV reported how researchers at the Hôpitaux de Paris and the Université Pierre et Marie Curie conducted a cross-sectional study with COVID-19 out- and inpatients. They produced findings strongly suggesting that current smokers have a very much lower probability of developing symptomatic or severe COVID-19 infection as compared to the general population.
Jean-Pierre Changeux and the internal medicine team at the Pitié Salpétrière hospital are going to see if the proposition that nicotine might reduce COVID-19 severity has legs.
They have already looked at 350 hospitalised patients and 130 outpatients. All patients tested positive for the virus. Then they looked to see if the patients smoked more or less than the general population of the same sex or the same age, by comparing with general population data dating from 2018. They found very few smokers.
Zahir Amoura, a Professor of Internal Medicine, said: “We found only 5% of smokers in these patients, which is very low. Basically, we have 80% less smokers in COVID patients than in the general population of same sex and same age.”
The rate of smoking in the general population in France is 24%.
Jean-Pierre Changeux hypothesised that nicotine could occupy receptors, preventing the virus from fixing itself. He reasoned it might prohibit the virus’ propagation and would put a brake on the development of the disease.
They plan on conducting a study to see if the use of nicotine patches is useful in reducing symptoms and it has been reported that the Minister of Health Olivier Véran and the Director General of Health Jérôme Salomon have shown interest in the study.
Once the study has been given the go-ahead, nicotine patches will be administered to three groups of patients at different dosage levels. The groups will consist of caregivers, to hospital patients, and to patients experiencing critical symptoms.
Dr Farsalinos’ paper that sparked the initial interest is still in pre-print stage. POTV plans on covering it when it has been peer-reviewed and published.
Related:
- “Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19” by Miyara, Tubach, POURCHER, Morelot-Panzini, Pernet, Haroche, Lebbah, Morawiec, Gorochov, Caumes, Hausfater, COMBES, Similowski, and Amoura – [link]
- “La nicotine, une arme contre le Covid?”, France Inter – [link]
Dave Cross
Journalist at POTVDave is a freelance writer; with articles on music, motorbikes, football, pop-science, vaping and tobacco harm reduction in Sounds, Melody Maker, UBG, AWoL, Bike, When Saturday Comes, Vape News Magazine, and syndicated across the Johnston Press group. He was published in an anthology of “Greatest Football Writing”, but still believes this was a mistake. Dave contributes sketches to comedy shows and used to co-host a radio sketch show. He’s worked with numerous vape companies to develop content for their websites.
Join the discussion
Harm Reduction For The Rich
The United Kingdom risks becoming a harm reduction country only for the wealthy, according to Michael Landl of the World Vapers’ Alliance
-
by Dave Cross
Longfills as an Alternative to Disposables
The disposable vape ban will impact many people, but there’s no reason to be concerned… Grab yourself a pod kit and a Longfill and you’ll be back to vaping the way you want to, just in a cheaper, more environmentally friendly and legal way.
COP10 is a Threat to Safer Nicotine Products
The EU obscures its position on low-risk alternatives to smoking before the WHO COP10 conference in Panama, starting Monday
-
by Dave Cross
Nicotine Is Not A Culprit
Planet of the Vapes has always encouraged smokers to use the quit product that works best for them, and snus is a product that seems to be unfairly blocked because it contains nicotine
-
by Dave Cross
